Bernstein Upgrades Amgen (AMGN) to Outperform
More News related to AMGN
- Amgen Highlights Data to be Presented at ASH
- Beacon Equity Issues Technical Trading Overview for NexMed Inc.
- Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards
- Amgen to Present at Lazard Capital Healthcare Conference
- Amgen to Present at 18th Annual Credit Suisse Healthcare Conference
More News related to Upgrades
- Airline Stocks Rising Again as Morgan Stanley Upgrades Sector to 'Attractive' (AMR, UAUA, ALK, ALGT)
- Thomas Weisel Upgrades Gildan Activewear (GIL) to Marketweight
- Credit Suisse Upgrades BB&T Corp (BBT) to Neutral
- BB&T Capital Upgrades Sysco (SYY) to Buy
- UBS Upgrades ARRIS Group (ARRS) to Buy
Sanford C. Bernstein upgrades Amgen (Nasdaq: AMGN) from Market Perform to Outperform.
For more analyst ratings on AMGN click here.
Amgen Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology.
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
